Particularly favorable in patients with low prostate-specific antigen (PSA) level, both of them provide superior sensitivity and specificity profiles for recurrent or metastatic prostate cancer than the earlier approved PET radiotracers (e.g., [18F]fluciclovine and [11C]choline). The gene discussed is KLK3; the disease is metastatic prostate carcinoma.